Prominent Research Scientist at Wayne State University School of Medicine Announces Positive Results for Anti-Inflammatory Properties of Health Enhancement Products, Inc. Proalgazyme(R) Compound

Company to Host Investor Conference Call Upon Patent Filing

| Source: Health Enhancement Products, Inc.

DETROIT, Nov. 3, 2009 (GLOBE NEWSWIRE) -- Professor of Pathology Dr. Fazlul Sarkar, conducting tests at Wayne State University School of Medicine, advised Health Enhancement Products, Inc. (OTCBB:HEPI) principals that results point to effective and significant management of inflammation at the cellular level without stimulating undesirable side effects.

"This may be a breakthrough in the management of inflammation, whether that inflammation is caused by metabolic issues, injury or disease. There are few, if any, anti-inflammatory bioactive compounds that exhibit a similar range of desirable benefits with little or no measurable unwanted side effects," states Fazlul Sarkar, Ph.D. "We're looking forward to conducting additional tests to study further the anti-inflammatory properties exhibited by the ProAlgaZyme(R) product."

The tests were conducted using human cells in culture which were then exposed to an array of stimulants. In some of the tests, cellular secretions were then drawn off and analyzed for anti-inflammatory activity, while in others proteins were extracted for assessment. ProAlgaZyme(R) is a proprietary bioactive compound developed and owned by Health Enhancement Products, Inc. which has completed a series of comprehensive tests and assays as part of its intellectual property development initiative which has resulted in a number of new patent applications.

The results, although characterized as preliminary until a formal paper is presented for peer review, point to significant and marked inhibition of certain inflammatory processes at the cellular level. The Company continues to protect its intellectual property by filing patent applications and taking other steps to ensure that the value of its intellectual property is maximized. Once patent applications are completed over the next several weeks, the Company will disclose additional information relevant to these test results.

Peter Vitulli, Interim CEO of Health Enhancement Products commented, "As I have previously stated, we have continued to conduct additional tests on our lead bioactive compound, ProAlgaZyme(R). Dr. Sarkar's study is truly remarkable and can lead to numerous opportunities for the Company. Given the tremendous sensitivity to protecting our assets, we have asked Dr. Sarkar to withhold specific results while we complete our official patent filing. Mr. Vitulli continued, "As a result of these recent developments, coupled with additional testing which continues, the Company will host a conference call upon completing the filing of the patents to discuss this and other recent developments. Based on current information and timing, we expect to hold the conference call later this month with additional details to follow."

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTCBB:HEPI) is a health & wellness company engaged in the development of dietary supplements and food additives comprised of pure, all-natural compounds. The Company's product is ProAlgaZyme(R) (PAZ(TM)), a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme.

About Dr. Fazlul Sarkar

Dr. Fazlul Sarkar is Professor of Pathology, Department of Pathology, Karmanos Cancer Center at Wayne State University School of Medicine; author of scientific papers on cancer chemoprevention, inflammation management; Senior Editor for Molecular Cancer Therapeutics journal and also holds patents relating to discoveries in cancer research.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

For more information, please visit

Health Enhancement Products, Inc.
IR Contact:
Howard Gostfrand/David Sasso